Weighing in on Optimal Management of VTE in Patients With Obesity

CE / CME

Weighing in on Optimal Management of VTE in Patients With Obesity
Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: April 15, 2022

Expiration: April 14, 2023

Christian T. Ruff
Christian T. Ruff, MD, MPH
Daniel Thibodeau
Daniel Thibodeau, DHSc, MHP, PA-C

Pretest

Progress
1 2
Course Completed
1.
Which of the following DOACs are recommended by the International Society on Thrombosis and Haemostasis 2021 update for patients with a BMI >40 kg/m2?
2.
Trial data on DOACs has indicated which of the following?
3.
How often do you currently educate your patients with obesity on the safety and efficacy profiles of DOACs vs warfarin?
4.
How often do you currently select a DOAC over warfarin in patients with obesity?
5.
How often do you assess patient risk factors for VTE recurrence and bleeding to determine the appropriate length of anticoagulation therapy?